| Identification | Back Directory | [Name]
N-[3-(benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]-N-[(4-fluorophenyl)methyl]acetamide | [CAS]
355406-76-7 | [Synonyms]
RIPGBM
N-[3-(benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl]-N-[(4-fluorophenyl)methyl]acetamide
Acetamide, N-[1,4-dihydro-1,4-dioxo-3-[(phenylmethyl)amino]-2-naphthalenyl]-N-[(4-fluorophenyl)methyl]- | [Molecular Formula]
C26H21FN2O3 | [MDL Number]
MFCD05670032 | [MOL File]
355406-76-7.mol | [Molecular Weight]
428.45 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 33.33 mg/mL (77.79 mM; Need ultrasonic) | [form ]
A crystalline solid | [color ]
Pink to red |
| Hazard Information | Back Directory | [Biological Activity]
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 of ≤500 nM[1].
RIPGBM induces caspase 1-dependent apoptosis by binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a molecular switch, which reduces the formation of a prosurvival RIPK2/ TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex[1]. | [storage]
Store at -20°C | [References]
[1]. Lucki NC, et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. |
|
| Company Name: |
commedx
|
| Tel: |
010-46598925 18519000250 |
| Website: |
www.commedx.com |
|